LVEF: Left ventricular ejection fraction; TEAEs: Treatment emergent adverse
No new safety signals in long-term
All grade TEAEs in patients who continued on monotherapy (10% in either
*Safety data are cumulative from start of monotherapy at 24 weeks
through 36 months of
follow-up from the last patient on study.
LVEF: Left ventricular ejection fraction; TEAEs: Treatment emergent
Connect with us for news and updates related to OGIVRI® (trastuzumab-dkst) injection.
*All fields required
You are now leaving ogivrihcp.com a Biocon Biologics Inc. company website.
The website you are about to access is not owned or controlled by Biocon Biologics. Links to other websites are provided as a convenience to users and the inclusion of any link does not imply the endorsement of the linked site by Biocon Biologics. Biocon Biologics accepts no responsibility for the content of any linked sites.